• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评价 KORTUC II 新放疗方案对 I 期和 II 期老年乳腺癌患者肿瘤阴影和乳腺 X 线摄影微钙化变化的影响,该方案无需任何手术。

Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.

机构信息

Department of Diagnostic Radiology & Radiation Oncology, Medical school, Kochi University Nankoku, Kochi 783-8505, Japan.

出版信息

Cancers (Basel). 2011 Sep 9;3(3):3496-505. doi: 10.3390/cancers3033496.

DOI:10.3390/cancers3033496
PMID:24212965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3759207/
Abstract

We introduced non-surgical therapy with a novel enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) into early stages breast cancer treatment. The purpose of this study was to examine changes in tumor shadows and microcalcifications on mammography (MMG) following KORTUC II for elderly patients with breast cancer. We also sought to determine whether MMG was useful in evaluating the therapeutic effect of KORTUC II. In addition to MMG, positron emission tomography-computed tomography (PET-CT) was performed to detect both metastasis and local recurrence. In all 10 patients, tumor shadows on MMG completely disappeared in several months following the KORTUC II treatment. The concomitant microcalcifications also disappeared or markedly decreased in number. Disappearance of the tumors was also confirmed by the profile curve of tumor density on MMG following KORTUC II treatment; density fell and eventually approached that of the peripheral mammary tissue. These 10 patients have so far have also shown neither local recurrence nor distant metastasis on PET-CT with a mean follow-up period of approximately 27 months at the end of September, 2010. We conclude that breast-conservation treatment using KORTUC II, followed by aromatase inhibitor, is a promising therapeutic method for elderly patients with breast cancer, in terms of avoiding any surgical procedure. Moreover, MMG is considered to be useful for evaluating the efficacy of KORTUC II.

摘要

我们将一种新型的酶靶向增敏放射治疗——Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II(KORTUC II)引入早期乳腺癌的治疗中。本研究的目的是探讨 KORTUC II 治疗老年乳腺癌患者后乳腺 X 线摄影(MMG)上肿瘤阴影和微钙化的变化,并确定 MMG 是否有助于评估 KORTUC II 的治疗效果。除了 MMG 之外,我们还进行了正电子发射断层扫描-计算机断层扫描(PET-CT),以检测转移和局部复发。在所有 10 例患者中,KORTUC II 治疗后数月内 MMG 上的肿瘤阴影完全消失。同时存在的微钙化也消失或明显减少。MMG 上的肿瘤密度曲线也证实了肿瘤的消失,密度下降,最终接近周围乳腺组织的密度。截至 2010 年 9 月底,这些患者的平均随访时间约为 27 个月,在 PET-CT 上均未发现局部复发或远处转移。我们的结论是,对于老年乳腺癌患者,KORTUC II 联合芳香酶抑制剂进行保乳治疗,避免了手术,是一种很有前途的治疗方法。此外,MMG 被认为有助于评估 KORTUC II 的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/b436179d53e1/cancers-03-03496f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/d016f11a83df/cancers-03-03496f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/97c6d4827923/cancers-03-03496f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/b436179d53e1/cancers-03-03496f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/d016f11a83df/cancers-03-03496f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/97c6d4827923/cancers-03-03496f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6198/3759207/b436179d53e1/cancers-03-03496f3.jpg

相似文献

1
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.评价 KORTUC II 新放疗方案对 I 期和 II 期老年乳腺癌患者肿瘤阴影和乳腺 X 线摄影微钙化变化的影响,该方案无需任何手术。
Cancers (Basel). 2011 Sep 9;3(3):3496-505. doi: 10.3390/cancers3033496.
2
Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging.采用乳腺对比增强磁共振成像评估不可切除癌肿 II 型(KORTUC II)患者接受新型增敏治疗 Kochi Oxydol-放射治疗的治疗反应:I/II 期乳腺癌患者的初步结果
Cancers (Basel). 2015 Dec 22;8(1):1. doi: 10.3390/cancers8010001.
3
Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy.局部晚期乳腺癌的非手术治疗:一种新的酶靶向增敏放射治疗——Kochi Oxydol 放射治疗不可切除癌,Ⅱ型(KORTUC Ⅱ)联合全身化疗的放射学评估治疗效果。
Oncol Rep. 2010 Nov;24(5):1161-8. doi: 10.3892/or_00000968.
4
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.对于接受表柔比星和环磷酰胺或紫杉烷诱导化疗后的IV期原发性乳腺癌患者的残留病灶,一种新型酶靶向放射增敏治疗(KORTUC II)的治疗反应。
Oncol Lett. 2017 Jan;13(1):69-76. doi: 10.3892/ol.2016.5456. Epub 2016 Dec 1.
5
Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II).I期乳腺癌新型酶靶向放射增敏治疗的非手术疗法及放射学评估:高知过氧化物酶放射治疗不可切除癌,II型(KORTUC II)
Exp Ther Med. 2010 Sep;1(5):769-775. doi: 10.3892/etm.2010.123. Epub 2010 Jul 20.
6
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer.复发性乳腺癌患者对一种新型酶靶向放射增敏治疗(高知过氧化氢放射治疗不可切除癌)的治疗反应。
Oncol Lett. 2016 Jul;12(1):29-34. doi: 10.3892/ol.2016.4589. Epub 2016 May 16.
7
Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.新型酶靶向放射增敏治疗(高知过氧化氢放射治疗)用于I期原发性乳腺癌患者不可切除癌的II期治疗结果
Oncol Lett. 2017 Jun;13(6):4741-4747. doi: 10.3892/ol.2017.6074. Epub 2017 Apr 21.
8
Non-Surgical Breast-Conserving Treatment (KORTUC-BCT) Using a New Radiosensitization Method (KORTUC II) for Patients with Stage I or II Breast Cancer.采用新的放射增敏方法(KORTUC II)对I期或II期乳腺癌患者进行非手术保乳治疗(KORTUC-BCT)
Cancers (Basel). 2015 Nov 17;7(4):2277-89. doi: 10.3390/cancers7040891.
9
Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II).含过氧化氢和透明质酸钠的新型放射增敏剂用于局部肿瘤注射的I期研究:一种新的酶靶向放射增敏治疗,高知氧多醇-不可切除癌放射治疗II型(KORTUC II)
Int J Oncol. 2009 Mar;34(3):609-18. doi: 10.3892/ijo_00000186.
10
Computed Tomography Demonstration of the Production and Distribution of Oxygen Gas Following Intratumoral Injection of a New Radiosensitizer (KORTUC) for Patients with Breast Cancer-Is Intratumoral Injection Not an Ideal Approach to Solve the Major Problem of Tumor Hypoxia in Radiotherapy?计算机断层扫描显示新型放射增敏剂(KORTUC)瘤内注射后乳腺癌患者体内氧气的产生与分布——瘤内注射是否并非解决放疗中肿瘤缺氧这一主要问题的理想方法?
Cancers (Basel). 2016 Apr 1;8(4):43. doi: 10.3390/cancers8040043.

引用本文的文献

1
Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.新型酶靶向放射增敏治疗(高知过氧化氢放射治疗)用于I期原发性乳腺癌患者不可切除癌的II期治疗结果
Oncol Lett. 2017 Jun;13(6):4741-4747. doi: 10.3892/ol.2017.6074. Epub 2017 Apr 21.
2
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.对于接受表柔比星和环磷酰胺或紫杉烷诱导化疗后的IV期原发性乳腺癌患者的残留病灶,一种新型酶靶向放射增敏治疗(KORTUC II)的治疗反应。
Oncol Lett. 2017 Jan;13(1):69-76. doi: 10.3892/ol.2016.5456. Epub 2016 Dec 1.
3

本文引用的文献

1
Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II).I期乳腺癌新型酶靶向放射增敏治疗的非手术疗法及放射学评估:高知过氧化物酶放射治疗不可切除癌,II型(KORTUC II)
Exp Ther Med. 2010 Sep;1(5):769-775. doi: 10.3892/etm.2010.123. Epub 2010 Jul 20.
2
Development of a novel enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide for intratumoral injection for patients with low linear energy transfer-radioresistant neoplasms.开发一种新型的酶靶向放射增敏剂(KORTUC),其含有过氧化氢,用于低线性能量传递放射抗性肿瘤患者的瘤内注射。
Oncol Lett. 2010 Nov;1(6):1025-1028. doi: 10.3892/ol.2010.184. Epub 2010 Sep 23.
3
Computed Tomography Demonstration of the Production and Distribution of Oxygen Gas Following Intratumoral Injection of a New Radiosensitizer (KORTUC) for Patients with Breast Cancer-Is Intratumoral Injection Not an Ideal Approach to Solve the Major Problem of Tumor Hypoxia in Radiotherapy?计算机断层扫描显示新型放射增敏剂(KORTUC)瘤内注射后乳腺癌患者体内氧气的产生与分布——瘤内注射是否并非解决放疗中肿瘤缺氧这一主要问题的理想方法?
Cancers (Basel). 2016 Apr 1;8(4):43. doi: 10.3390/cancers8040043.
4
Paradigm Shift in Radiation Biology/Radiation Oncology-Exploitation of the "H₂O₂ Effect" for Radiotherapy Using Low-LET (Linear Energy Transfer) Radiation such as X-rays and High-Energy Electrons.放射生物学/放射肿瘤学的范式转变——利用“过氧化氢效应”进行使用低传能线密度(LET)辐射(如X射线和高能电子)的放射治疗。
Cancers (Basel). 2016 Feb 25;8(3):28. doi: 10.3390/cancers8030028.
5
Development of a Novel Enzyme-Targeting Radiosensitizer (New KORTUC) Using a Gelatin-Based Hydrogel Instead of a Sodium Hyaluronate.使用基于明胶的水凝胶而非透明质酸钠开发新型酶靶向放射增敏剂(新型KORTUC)。
Cancers (Basel). 2016 Jan 7;8(1):10. doi: 10.3390/cancers8010010.
6
Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging.采用乳腺对比增强磁共振成像评估不可切除癌肿 II 型(KORTUC II)患者接受新型增敏治疗 Kochi Oxydol-放射治疗的治疗反应:I/II 期乳腺癌患者的初步结果
Cancers (Basel). 2015 Dec 22;8(1):1. doi: 10.3390/cancers8010001.
7
Non-Surgical Breast-Conserving Treatment (KORTUC-BCT) Using a New Radiosensitization Method (KORTUC II) for Patients with Stage I or II Breast Cancer.采用新的放射增敏方法(KORTUC II)对I期或II期乳腺癌患者进行非手术保乳治疗(KORTUC-BCT)
Cancers (Basel). 2015 Nov 17;7(4):2277-89. doi: 10.3390/cancers7040891.
Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors.新型酶靶向增敏放射治疗(KORTUC II)瘤内注射治疗低 LET 抵抗性肿瘤的安全性和有效性。
Int J Oncol. 2011 Sep;39(3):553-60. doi: 10.3892/ijo.2011.1069. Epub 2011 Jun 6.
4
Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy.局部晚期乳腺癌的非手术治疗:一种新的酶靶向增敏放射治疗——Kochi Oxydol 放射治疗不可切除癌,Ⅱ型(KORTUC Ⅱ)联合全身化疗的放射学评估治疗效果。
Oncol Rep. 2010 Nov;24(5):1161-8. doi: 10.3892/or_00000968.
5
Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells.过氧化氢与X射线联合处理可诱导人前列腺癌PC-3细胞凋亡。
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):449-54. doi: 10.1016/j.ijrobp.2009.04.092.
6
Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II).含过氧化氢和透明质酸钠的新型放射增敏剂用于局部肿瘤注射的I期研究:一种新的酶靶向放射增敏治疗,高知氧多醇-不可切除癌放射治疗II型(KORTUC II)
Int J Oncol. 2009 Mar;34(3):609-18. doi: 10.3892/ijo_00000186.
7
New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms.使用过氧化氢溶液浸湿的纱布推注对不可切除且表面暴露的肿瘤进行新的放射增敏治疗(KORTUC I)。
Oncol Rep. 2008 Jun;19(6):1389-94.
8
Immunocytochemical characteristics of human osteosarcoma cell line HS-Os-1: possible implication in apoptotic resistance against irradiation.人骨肉瘤细胞系HS-Os-1的免疫细胞化学特征:对辐射诱导凋亡抵抗的潜在影响
Int J Mol Med. 2004 Sep;14(3):397-403.
9
Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation is converted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as a new radiosensitizer.人骨肉瘤细胞系HS-Os-1对辐射的凋亡抗性通过过氧化氢转化为凋亡敏感性:过氧化氢作为一种新型放射增敏剂的重要作用。
Int J Mol Med. 2003 Dec;12(6):845-50.
10
Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation.人骨肉瘤细胞系HS-Os-1对辐射的凋亡抗性机制
Int J Mol Med. 2003 Oct;12(4):453-8.